The estimated Net Worth of Christian Weyer is at least $1.12 Million dollars as of 27 April 2020. Christian Weyer owns over 181 units of Intercept Pharmaceuticals Inc stock worth over $325,660 and over the last 11 years he sold ICPT stock worth over $793,326. In addition, he makes $0 as Executive Vice President - Research & Development at Intercept Pharmaceuticals Inc.
Christian has made over 12 trades of the Intercept Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 181 units of ICPT stock worth $15,557 on 27 April 2020.
The largest trade he's ever made was exercising 25,000 units of Intercept Pharmaceuticals Inc stock on 13 April 2015 worth over $34,250. On average, Christian trades about 1,442 units every 65 days since 2014. As of 27 April 2020 he still owns at least 17,140 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Christian Weyer stock trades at the bottom of the page.
Dr. Christian Weyer M.D. M.A.S. serves as Executive Vice President - Research & Development of the Company. Dr. Weyer’s career in metabolic drug development spans more than 20 years, involving clinical studies and regulatory submissions at all stages of product development and across the continuum of diabetes, obesity and NAFLD/NASH. Prior to joining the Company, Dr. Weyer was President and Chief Development Officer at ProSciento, Inc., a leading clinical R&D service provider focused on diabetes, NAFLD/NASH and obesity, from December 2015 to November 2017. Dr. Weyer has served as a senior executive in several companies, including as President, Chief Executive Officer and a director of Fate Therapeutics, Inc. from October 2012 to November 2015, where he steered the company’s transition into a publicly traded cellular therapeutics company, and as Senior Vice President of R&D at Amylin Pharmaceuticals, Inc., where he contributed to the development and approval of several first-in-class medicines for diabetes and lipodystrophy. Before joining Amylin, Dr. Weyer worked at the National Institutes of Health, NIDDK, conducting clinical research on the pathogenesis of obesity and type 2 diabetes. Dr. Weyer received his M.D. and clinical training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany and holds a postdoctoral master’s degree in advanced clinical research from the University of California, San Diego.
Christian Weyer is 51, he's been the Executive Vice President - Research & Development of Intercept Pharmaceuticals Inc since 2017. There are 16 older and 5 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Christian's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK, NY, 10001.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: